Last reviewed · How we verify
NCT05667597: COVICO
Sars-COV-2 (COVID-19) Immunity in immunoCOmpromised Populations
NA trial testing Humoral immunity in SARS CoV 2 Infection in 350 participants. Participants enrolled and being followed up; not accepting new ones.
31 October 2026
Quick facts
| Lead sponsor | Maria Goossens |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 350 |
| Start date | 23 January 2023 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Humoral immunity
Conditions studied
- SARS CoV 2 Infection — all drugs for SARS CoV 2 Infection →
- COVID-19 — all drugs for COVID-19 →
Sponsor
Maria Goossens
Who can join
18 and older, any sex, with SARS CoV 2 Infection or COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The immune response of COVID-19 vaccination was monitored and studied in the context of the previously PICOV study (P2020/424), Nephro- VAC studies (P2020/284 and P2020/312) and Lung-VAC study (P2021/182). The constant emergence of new variants of concern (VOCs), which become increasingly better at escaping infection and vaccine induced immune responses, together with waning immunity over time, warrant additional vaccination rounds. This is especially true in immunocompromised populations. In the current study, we want to continue monitoring SARS-CoV-2 specific immunity over the next two years, encompassing several future vaccination campaigns.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05667597
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for SARS CoV 2 Infection
Currently open trials in the same condition.
- NCT07189936 — Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS · Phase 2 · recruiting
- NCT07197164 — Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients · Phase 2 · recruiting
- NCT06950177 — Pancoronavirus Vaccine Study in Healthy Adults · Phase 1 · active not recruiting
- NCT06640387 — CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools · recruiting
- NCT06633835 — Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United St · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05667597 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Maria Goossens
- Last refreshed: 6 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05667597.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing